Literature DB >> 27020588

Toward Observation as First-line Management in Abdominal Desmoid Tumors.

Sally M Burtenshaw1,2,3, Amanda J Cannell1,2,3, Edward D McAlister1,2,3, Saquib Siddique1,2,3, Rita Kandel4,5, Martin E Blackstein6,7, Carol J Swallow1,2,3, Rebecca A Gladdy8,9,10.   

Abstract

BACKGROUND: Desmoid tumors (DT) occur sporadically, in familial adenomatous polyposis, or in association with pregnancy. Initial observation has been proposed in the management of DT. An advantage of this approach is to select patients who have indolent disease versus those who require intervention. Here we report our multidisciplinary experience of abdominal DT as it relates to nonoperative management.
METHODS: Patients seeking care from 1980 to 2012 with pathologically confirmed DT were identified from clinical research databases. Clinicopathologic data and management strategies were collected, and statistical analyses were performed by Chi square and t tests.
RESULTS: A total of 213 patients were identified; DT occurred in abdominal wall (n = 103, 48 %), intra-abdominally (n = 92, 43 %), or at both sites (n = 18, 9 %). Patients were predominantly female (72 %); disease was sporadic (48 %), associated with familial adenomatous polyposis (38 %), or associated with pregnancy (14 %). Patient presentation was stratified into 3 groups: untreated (group A; n = 176), DT resected elsewhere (group B; n = 19), or recurrent DT (group C; n = 18). In group A, 109 patients were initially observed, with 51 patients requiring intervention as a result of progression or symptoms. Of the 58 patients who underwent only observation, 93 % experienced spontaneous regression or stable disease (median follow-up 38 months). Of the 67 patients in group A who underwent resection, 28 % experienced recurrence (median 22 months). Abdominal wall DT >7 cm and intra-abdominal DT were more likely to recur (P < 0.01).
CONCLUSIONS: Initial observation has been implemented for abdominal DT at our institution. Over half of patients observed required no intervention with prolonged follow-up. Tumor size and site may predict progression during observation, therefore representing higher-risk groups.

Entities:  

Mesh:

Year:  2016        PMID: 27020588     DOI: 10.1245/s10434-016-5159-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.

Authors:  Joanna Robles; Vahakn S Keskinyan; Matthew Thompson; Joseph T Davis; David Van Mater
Journal:  Pediatr Hematol Oncol       Date:  2020-03-04       Impact factor: 1.969

2.  Surgical management of abdominal desmoids: a systematic review and meta-analysis.

Authors:  Dave Moore; Lucy Burns; Ben Creavin; Eanna Ryan; Kevin Conlon; Michael Eamon Kelly; Dara Kavanagh
Journal:  Ir J Med Sci       Date:  2022-04-21       Impact factor: 1.568

3.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

4.  Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study.

Authors:  Michael R Cassidy; Robert A Lefkowitz; Niamh Long; Li-Xuan Qin; Amanda Kirane; Eman Sbaity; Meera Hameed; Daniel G Coit; Murray F Brennan; Samuel Singer; Aimeé M Crago
Journal:  Ann Surg       Date:  2020-04       Impact factor: 13.787

5.  Rapid progression of a pregnancy-associated intra-abdominal desmoid tumor in the post-partum period: A case report.

Authors:  David Hanna; Michail Magarakis; William S Twaddell; H Richard Alexander; Susan B Kesmodel
Journal:  Int J Surg Case Rep       Date:  2016-10-26

6.  Desmoid Tumours of the extremity and trunk. A retrospective study of 44 patients.

Authors:  Laura Wirth; Alexander Klein; Andrea Baur-Melnyk; Thomas Knösel; Lars H Lindner; Falk Roeder; Volkmar Jansson; Hans Roland Dürr
Journal:  BMC Musculoskelet Disord       Date:  2018-01-05       Impact factor: 2.362

7.  Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.

Authors:  Katrina M Ingley; Sally M Burtenshaw; Nicole C Theobalds; Lawrence M White; Martin E Blackstein; Rebecca A Gladdy; Seng Thipphavong; Abha A Gupta
Journal:  Cancer Med       Date:  2019-07-13       Impact factor: 4.452

Review 8.  An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).

Authors:  B Kasper; C Baumgarten; J Garcia; S Bonvalot; R Haas; F Haller; P Hohenberger; N Penel; C Messiou; W T van der Graaf; A Gronchi
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

9.  Spontaneous regression of a sporadic intra-abdominal located desmoid-type fibromatosis.

Authors:  Jurian Kloeze; Martin van Veen
Journal:  J Surg Case Rep       Date:  2019-02-12

10.  Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.

Authors:  Edoardo Zanchetta; Chiara Maura Ciniselli; Annalisa Bardelli; Chiara Colombo; Silvia Stacchiotti; Giacomo Giulio Baldi; Salvatore Provenzano; Rossella Bertulli; Federica Bini; Alessandra Casale; Francesca Gabriella Greco; Andrea Ferrari; Paolo Verderio; Marco Fiore; Alessandro Gronchi; Paolo Giovanni Casali; Carlo Morosi; Elena Palassini
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.